SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Bluegreen who wrote (13699)5/29/2000 10:47:00 AM
From: Tharos  Read Replies (1) | Respond to of 17367
 
Good commentary, but all this ignores one slightly pertinent fact...it has to recieve FDA approval first.

I find it interesting that George has slithered back to the board. Don't have any idea what he is saying because I have him on "ignore."

When the stock was in the teens he heads off with his own group. Guess even the new board could not prop up the stock's price.

Not to fear though, you will have the chance to do a little dollar cost averaging in the twos. IMHO.



To: Bluegreen who wrote (13699)5/29/2000 11:42:00 AM
From: Robert K.  Read Replies (1) | Respond to of 17367
 
Blue> yes i too feel confident that baxter will indeed get us to conclusion. They have the power and resources. IMO it
pretty much just a time question now. I beleiev the xoma-bax agreement protects xoma interests and we just need to let bax do their thing. Regarding dna, i see that as a partnership where xoma and dna BOTH see growing opportunity. Regarding allergan>everyone is underestimating
what and why allergan did this deal.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News